STEK Stock Overview
A stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Stemtech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.051 |
| 52 Week High | US$0.10 |
| 52 Week Low | US$0.01 |
| Beta | 1.82 |
| 11 Month Change | 38.49% |
| 3 Month Change | 33.95% |
| 1 Year Change | 44.29% |
| 33 Year Change | -98.43% |
| 5 Year Change | n/a |
| Change since IPO | -98.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| STEK | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 96.1% | 1.5% | -1.0% |
| 1Y | 44.3% | -13.9% | 30.3% |
Return vs Industry: STEK exceeded the US Personal Products industry which returned -13.9% over the past year.
Return vs Market: STEK exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| STEK volatility | |
|---|---|
| STEK Average Weekly Movement | 39.3% |
| Personal Products Industry Average Movement | 8.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: STEK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: STEK's weekly volatility has increased from 26% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Charles Arnold | www.stemtech.com |
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. Its products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. The company offers its dietary supplements products under the RCM System, stemrelease3, Stemflo MigraStem, and OraStem brand names; and skincare products under the Cellect One brand name.
Stemtech Corporation Fundamentals Summary
| STEK fundamental statistics | |
|---|---|
| Market cap | US$6.35m |
| Earnings (TTM) | -US$5.24m |
| Revenue (TTM) | US$5.10m |
1.2x
P/S Ratio-1.2x
P/E RatioIs STEK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STEK income statement (TTM) | |
|---|---|
| Revenue | US$5.10m |
| Cost of Revenue | US$1.28m |
| Gross Profit | US$3.82m |
| Other Expenses | US$9.06m |
| Earnings | -US$5.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 74.96% |
| Net Profit Margin | -102.67% |
| Debt/Equity Ratio | -74.8% |
How did STEK perform over the long term?
See historical performance and comparison